Insider Selling: Vericel (NASDAQ:VCEL) Director Sells $156,690.00 in Stock

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 3,000 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total value of $156,690.00. Following the completion of the transaction, the director owned 32,995 shares of the company’s stock, valued at approximately $1,723,328.85. This represents a 8.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vericel Price Performance

NASDAQ:VCEL opened at $54.62 on Monday. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $55.60. The stock has a fifty day simple moving average of $41.01 and a 200-day simple moving average of $38.90. The company has a market capitalization of $2.80 billion, a PE ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The firm had revenue of $85.37 million for the quarter, compared to analysts’ expectations of $77.95 million. During the same period in the prior year, the company earned $0.10 EPS. The firm’s revenue was up 26.5% on a year-over-year basis. As a group, equities analysts anticipate that Vericel Corporation will post 0.54 earnings per share for the current year.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Analyst Upgrades and Downgrades

VCEL has been the topic of several research reports. TD Cowen increased their price target on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. HC Wainwright lifted their price objective on Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group set a $60.00 target price on Vericel in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. Finally, Wall Street Zen raised Vericel from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.80.

Institutional Investors Weigh In On Vericel

Hedge funds have recently modified their holdings of the company. MCF Advisors LLC increased its stake in Vericel by 293.0% in the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 583 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in Vericel during the second quarter worth about $36,000. Allworth Financial LP acquired a new stake in Vericel in the 2nd quarter worth about $60,000. Meeder Asset Management Inc. acquired a new stake in Vericel in the 1st quarter worth about $61,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Vericel in the 2nd quarter valued at about $72,000.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.